Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Patrignani

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Current Pharmaceutical Design|February 18, 2004
Clinical pharmacology of novel selective COX-2 inhibitorsS Tacconelli, M L Capone, P Patrignani
The Journal of Clinical Investigation|July 4, 2001
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outsC Patrono, P Patrignani, L A García Rodríguez
Pharmacological Research|April 1, 1993
Differential effects of leukotriene C4 on endothelin-1 and prostacyclin release by cultured vascular cellsP Patrignani, R Modica, F Bertolero, et al.
Thrombosis and Haemostasis|July 1, 1995
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical developmentC Patrono, P Patrignani, B Rocca, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Effects of various prostaglandin synthesis inhibitors on the tone of the lower oesophageal sphincter in manM Cagossi, M Salgarello, P Patrignani, et al.
Biochemical and Biophysical Research Communications|October 29, 1987
Platelet-activating factor (PAF) receptor antagonists inhibit mitogen-induced human peripheral blood T-cell proliferationP Patrignani, S Valitutti, F Aiello, et al.
Journal of Thrombosis and Haemostasis : JTH|February 18, 2009
Risk of myocardial infarction persisting after discontinuation of non-steroidal anti-inflammatory drugs in the general populationL A García Rodríguez, P Patrignani, A González-Pérez
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1984
Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolismP Patrignani, P Filabozzi, F Catella, et al.
Annals of the New York Academy of Sciences|November 15, 1994
Eicosanoid biosynthesis and metabolism in myeloproliferative disordersC Patrono, G Ciabattoni, P Patrignani, et al.
International Journal of Immunopathology and Pharmacology|October 14, 2003
Clinical pharmacology of selective COX-2 inhibitorsM L Capone, S Tacconelli, M G Sciulli, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Current Pharmaceutical Design|February 18, 2004
Clinical pharmacology of novel selective COX-2 inhibitorsS Tacconelli, M L Capone, P Patrignani
The Journal of Clinical Investigation|July 4, 2001
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outsC Patrono, P Patrignani, L A García Rodríguez
Pharmacological Research|April 1, 1993
Differential effects of leukotriene C4 on endothelin-1 and prostacyclin release by cultured vascular cellsP Patrignani, R Modica, F Bertolero, et al.
Thrombosis and Haemostasis|July 1, 1995
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical developmentC Patrono, P Patrignani, B Rocca, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Effects of various prostaglandin synthesis inhibitors on the tone of the lower oesophageal sphincter in manM Cagossi, M Salgarello, P Patrignani, et al.
Biochemical and Biophysical Research Communications|October 29, 1987
Platelet-activating factor (PAF) receptor antagonists inhibit mitogen-induced human peripheral blood T-cell proliferationP Patrignani, S Valitutti, F Aiello, et al.
Journal of Thrombosis and Haemostasis : JTH|February 18, 2009
Risk of myocardial infarction persisting after discontinuation of non-steroidal anti-inflammatory drugs in the general populationL A García Rodríguez, P Patrignani, A González-Pérez
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1984
Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolismP Patrignani, P Filabozzi, F Catella, et al.
Annals of the New York Academy of Sciences|November 15, 1994
Eicosanoid biosynthesis and metabolism in myeloproliferative disordersC Patrono, G Ciabattoni, P Patrignani, et al.
International Journal of Immunopathology and Pharmacology|October 14, 2003
Clinical pharmacology of selective COX-2 inhibitorsM L Capone, S Tacconelli, M G Sciulli, et al.
Pageof 8